- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Global Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
38
5 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
38 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
688526 | CN¥14.75 | -4.4% | -19.7% | CN¥6.8b | CN¥20.20 | PE22.9x | E24.3% | 2.9% | ||
603707 | CN¥13.49 | -3.4% | -10.6% | CN¥21.8b | CN¥18.00 | PS5.6x | E70.5% | 0.7% | ||
GALD New | CHF 97.00 | 7.5% | n/a | CHF 23.0b | CHF 99.88 | PS6x | E44.6% | n/a | ||
6472 | NT$737.00 | -1.9% | 14.8% | NT$76.2b | NT$977.83 | PE19.5x | E16.2% | 1.6% | ||
688046 | CN¥13.90 | -1.6% | -28.3% | CN¥5.7b | CN¥16.75 | PE40.7x | E27.9% | 0.4% | ||
688166 | CN¥31.39 | -5.5% | -3.9% | CN¥13.2b | CN¥41.11 | PE70.4x | E34.8% | 0.3% | ||
TLX | AU$24.74 | 0.9% | 160.4% | AU$8.3b | AU$25.62 | PE168.3x | E38.3% | n/a | ||
4974 | JP¥992.00 | -4.8% | -16.9% | JP¥119.5b | JP¥1,466.67 | PE131.4x | E26.0% | 1.7% | ||
LLY | US$767.76 | -2.7% | 34.6% | US$691.3b | US$984.05 | PE82.6x | E29.8% | 0.8% | ||
A326030 | ₩102,100.00 | -3.6% | 9.2% | ₩8.0t | ₩121,928.57 | PE139.3x | E66.4% | n/a | ||
INDOCO | ₹339.95 | 1.4% | -15.0% | ₹31.3b | ₹312.40 | PE97.7x | E72.2% | 0.4% | ||
A214450 | ₩253,500.00 | 3.5% | 130.5% | ₩2.6t | ₩282,750.00 | PE29.7x | E27.9% | 0.4% | ||
BIOA B New | SEK 212.80 | 23.9% | -21.2% | SEK 18.8b | SEK 322.00 | PS112.5x | E62.5% | 0% | ||
OSTX New | US$3.97 | 31.5% | n/a | US$84.3m | US$12.67 | PE-11.4x | E3.3% | n/a | ||
002653 | CN¥34.60 | -2.2% | 64.1% | CN¥38.4b | CN¥42.38 | PE80.6x | E35.7% | 0.8% | ||
GXI | €67.65 | -10.9% | -28.9% | €2.3b | €112.92 | PE20.4x | E21.8% | 1.8% | ||
ACB | CA$6.15 | 0% | -3.9% | CA$337.3m | CA$8.75 | PS1.1x | E133.0% | n/a | ||
RMDA | ج.م3.39 | -3.1% | 108.4% | ج.م5.1b | ج.م5.02 | PE19.2x | E30.7% | 2.0% | ||
CDXC | US$5.49 | -10.3% | 278.6% | US$420.3m | US$7.96 | PE283x | E81.8% | n/a | ||
ARGX | €604.60 | 4.1% | 79.5% | €36.5b | €596.31 | PS20x | E55.7% | n/a | ||
GNS | UK£15.14 | -7.3% | -30.3% | UK£994.5m | UK£24.23 | PE125.9x | E31.5% | 2.1% | ||
RGEN | US$144.46 | -7.6% | -20.9% | US$8.1b | US$191.46 | PS12.8x | E51.8% | n/a | ||
300294 | CN¥30.78 | -0.3% | -7.7% | CN¥15.5b | CN¥36.70 | PE83.4x | E44.4% | 1.0% | ||
MLAB | US$132.08 | 3.5% | 25.7% | US$717.4m | US$133.33 | PS3.1x | E134.3% | 0.5% |